I've linked a countdown to ELTP uplisting. It's been a long ride, but in the latest earnings call the CEO stated that the company is extending the contract with M&A company Jeffries for another 6 months (the implication is that it is to continue working on a potential buyout with the large pharma company he referenced in the last earnings call in July). Whether that buyout happens or not, Nasrat explicitly stated that by the February earnings call the company should be already listed or about to be finalized. That's Feb 15th. Right before that, he stated they plan of filing the ANDA for the new anticonvulsant they just received a positive bioequivalence on. Lastly, he stated that he feels very confident that ELTP will be able to negotiate a 2028 entry into the generic version of the $27 Billion Eliquis that we filed an ANDA for a few months ago. Why is this of particular importance? When Actavis was able to navigate a similar solution back in 2013, guess who was integral to that accomplishment? ELTPs very own CEO, Nasrat Hakim.
I've always said this stock isnt' an "if" it's a "when". Now we have our "when" narrowly defined.
I'll be buying $2500 every single trading day until the February uplisting.